Part 2/5:
Novo Nordisk hailed the proposed policy change as an essential advancement for patients struggling with obesity. Currently, Medicare and Medicaid cover specific weight-loss drugs only for conditions like diabetes, leaving obesity itself uncovered. The proposed changes by the White House would not only broaden this scope but also potentially come into effect within a two-year timeframe.